Ionis Q2 FY26 revenue drops 40.71% to $268 million; operating loss widens to $102 million

• Ionis posted Q2 GAAP revenue of $268 million, down 40.71% year over year; operating loss widened to $102 million from operating income of $140 million.
• GAAP net loss was $115 million, swinging from net income of $124 million; diluted loss per share was $0.69 versus earnings per share of $0.70.
• Commercial revenue rose 15% to $119 million, while R&D revenue fell 57.31% to $149 million, excluding a prior-year one-time sapablursen upfront payment.
• TRYNGOLZA generated net product sales of $5 million, DAWNZERA delivered $26 million; cash and short-term investments were $2.1 billion at June 30.
• Management cited early TRYNGOLZA sHTG launch momentum, expects Alexander disease decision for zilganersen by Sept. 22, 2026, and reiterated it is on track for 2026 guidance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.